Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pimecrolimus

FDA-approved product (cream, topical), marketed as Elidel, Pimecrolimus.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Pimecrolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eczematoid dermatitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pimecrolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pimecrolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema

    NCT00946478 · start 2009-10

    Registered record
    Registry ID
    NCT00946478
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus; Vehicle cream
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-10
    Completion
    2011-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus; Vehicle cream
    PhaseNot applicable
    Registry statusCompleted

  • Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

    NCT01177566 · start 2009-09

    Registered record
    Registry ID
    NCT01177566
    Conditions
    Atopic Dermatitis
    Interventions
    pimecrolimus; topical medical device
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2010-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    Interventionpimecrolimus; topical medical device
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound

    NCT00655512 · start 2008-01

    Registered record
    Registry ID
    NCT00655512
    Conditions
    Healthy
    Interventions
    pimecrolimus 1% cream; hydrocortisonacetat 1% cream; betamethasonvalerat 0,1% cream; clobetasol-17-propionat 0,05% cream; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionpimecrolimus 1% cream; hydrocortisonacetat 1% cream; betamethasonvalerat 0,1% cream; clobetasol-17-propionat 0,05% cream +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis

    NCT00568412 · start 2007-12

    Registered record
    Registry ID
    NCT00568412
    Conditions
    Mild to Moderate Atopic Dermatitis
    Interventions
    Zarzenda; Elidel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild to Moderate Atopic Dermatitis
    InterventionZarzenda; Elidel
    PhasePhase 4
    Registry statusCompleted

  • A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

    NCT00403559 · start 2007-05-07

    Registered record
    Registry ID
    NCT00403559
    Conditions
    Seborrheic Dermatitis
    Interventions
    Elidel; Ketoconazole Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05-07
    Completion
    2009-02-27
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeborrheic Dermatitis
    InterventionElidel; Ketoconazole Cream
    PhasePhase 2
    Registry statusCompleted

  • Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

    NCT00460083 · start 2007-04

    Registered record
    Registry ID
    NCT00460083
    Conditions
    Atopic Dermatitis
    Interventions
    Elidel(R) (pimecrolimus 1%); EpiCeram(R) -ceramide based barrier repair cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-04
    Completion
    2008-02
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionElidel(R) (pimecrolimus 1%); EpiCeram(R) -ceramide based barrier repair cream
    PhasePhase 4
    Registry statusCompleted

  • Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children

    NCT00810862 · start 2006-11

    Registered record
    Registry ID
    NCT00810862
    Conditions
    Atopic Dermatitis
    Interventions
    pimecrolimus active cream; placebo base cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2006-11
    Completion
    2008-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    Interventionpimecrolimus active cream; placebo base cream
    PhasePhase 4
    Registry statusTerminated

  • Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

    NCT00393263 · start 2006-10

    Registered record
    Registry ID
    NCT00393263
    Conditions
    Lichen Sclerosus
    Interventions
    pimecrolimus and clobetasol; clobetasol 0.05% cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-10
    Completion
    2009-10
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Sclerosus
    Interventionpimecrolimus and clobetasol; clobetasol 0.05% cream
    PhasePhase 2
    Registry statusCompleted

  • A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)

    NCT00322569 · start 2006-07

    Registered record
    Registry ID
    NCT00322569
    Conditions
    Coronary Disease
    Interventions
    Corio™ Pimecrolimus-Eluting Coronary Stent System; SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System; Costar ™ Paclitaxel-Eluting Coronary Stent System
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-07
    Completion
    2012-05
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Disease
    InterventionCorio™ Pimecrolimus-Eluting Coronary Stent System; SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System; Costar ™ Paclitaxel-Eluting Coronary Stent System
    PhasePhase 3
    Registry statusCompleted

  • Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)

    NCT00322543 · start 2006-05

    Registered record
    Registry ID
    NCT00322543
    Conditions
    Coronary Disease
    Interventions
    Corio™ Pimecrolimus-eluting stent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-05
    Completion
    2008-05
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Disease
    InterventionCorio™ Pimecrolimus-eluting stent
    PhasePhase 3
    Registry statusTerminated

  • Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus

    NCT00608673 · start 2006-04

    Registered record
    Registry ID
    NCT00608673
    Conditions
    Discoid Lupus Erythematosus
    Interventions
    Pimecrolimus 1% cream; betamethasone valerate 0.1% cream
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-11
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiscoid Lupus Erythematosus
    InterventionPimecrolimus 1% cream; betamethasone valerate 0.1% cream
    PhaseNot applicable
    Registry statusCompleted

  • Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis

    NCT00367393 · start 2006-03

    Registered record
    Registry ID
    NCT00367393
    Conditions
    Atopic Dermatitis
    Interventions
    Pimecrolimus cream 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2007-12
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionPimecrolimus cream 1%
    PhasePhase 4
    Registry statusCompleted

  • Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

    NCT00377962 · start 2005-12

    Registered record
    Registry ID
    NCT00377962
    Conditions
    Disorder Related to Cardiac Transplantation
    Interventions
    Everolimus; Mycophenolic acid (MPA)/azathioprine (AZA); Calcineurin inhibitors (CNI); Steroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-12
    Completion
    2010-02
    Enrolment
    282

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisorder Related to Cardiac Transplantation
    InterventionEverolimus; Mycophenolic acid (MPA)/azathioprine (AZA); Calcineurin inhibitors (CNI); Steroids
    PhasePhase 4
    Registry statusCompleted

  • Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

    NCT00208026 · start 2005-09

    Registered record
    Registry ID
    NCT00208026
    Conditions
    Netherton Syndrome
    Interventions
    Pimecrolimus 1% Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2008-03
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNetherton Syndrome
    InterventionPimecrolimus 1% Cream
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis

    NCT00232115 · start 2005-09

    Registered record
    Registry ID
    NCT00232115
    Conditions
    Perioral Dermatitis
    Interventions
    Pimecrolimus; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-09
    Completion
    2006-07
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerioral Dermatitis
    InterventionPimecrolimus; Placebo
    PhasePhase 3
    Registry statusCompleted